Xeris Biopharma Holdings, Inc.

XERS · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders3.1%

Institutions60.1%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2021-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$291.85M	$203.07M	$163.91M	$49.28M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$24.90M	-$33.65M	-$44.01M	-$115.16M
Operating income as a percentage of revenue.	8.5%	-16.6%	-26.8%	-233.7%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$554000	-$54.84M	-$62.26M	-$122.72M
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.00	$0.00	$0.00	$-1.55
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$0.00	$0.00	$0.00	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2021-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$111.00M	$71.62M	$67.45M	$67.27M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$383.53M	$323.06M	$322.60M	$304.36M
All of the company's interest-bearing borrowings, short and long term combined.	$220.34M	$232.11M	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$369.84M	$352.68M	$329.38M	$209.13M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$13.69M	-$29.61M	-$6.78M	$95.23M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2021-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$28.63M	-$36.98M	-$47.02M	-$95.53M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	–	–	$1.08M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	–	–	-$96.62M

	You	Peer avg
P/E	–	10.3
Revenue Growth	+28.7%	-4.5%
ROE	–	-19.3%

Xeris Biopharma Holdings, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison